Phase III data on Cystoscopy with Cysview shows detection of significant numbers of patients with recurrence of bladder cancer- Photocure

Photocure has announced that new Phase III study results with Blue Light Flexible Cystoscopy (BLFC) with Hexvix/Cysview showed that BLFC with Cysview detected bladder cancer recurrence in 21.5% of the patients undergoing surveillance cystoscopy that otherwise would have been missed with white light (WL) alone, which is highly significant (p<0.0001). of note the study showed that nine out of twenty-six patients 34.6 with flat more aggressive high grade lesions carcinoma in situ cis were diagnosed using confirmatory blue light cystoscopy with cysview alone and not wl p><0.0001).>

The study also showed that there was no increase in the rate of related adverse events after repeated administration of Cysview in bladder cancer patients undergoing cystoscopy examination. The study was a prospective, open, comparative, within-patient controlled study, included 304 patients with non-muscle invasive bladder cancer (NMIBC) enrolled at 17 academic institutions in the US. In the study BLFC with Cysview was used with the KARL STORZ D-LIGHT C PDD Flexible Videoscope System. Data were presented during a late-breaking plenary session at the American Urological Association (AUA) Annual Meeting.